To
Dr. G. N. Singh,
The Drugs Controller General of India,
New Delhi

Dear Dr. Singh,

As discussed on 1st April 2016 in your office, here is the modification IADVL would like in schedule H. Deletion of the phrase “excluding those intended for topical or external use (except ophthalmic and ear / nose preparations containing antibiotics and/or steroids” would be the first step towards preventing OTC sales and advertisements of topical steroids.

Below is the list of topical steroids to be included in schedule H:

- Alclometasone
- Beclomethasone
- Desonide
- Desoximetasone
- Dexamethasone
- Diflorasone diacetate
- Fluocinonide
- Fluocinolone acetonide
- Halobetasol propionate
- Halometasone
- Hydrocortisone
- Methylprednisone aceponate
- Prednicarbate
- Triamcinolone acetonide

Betamethasone, clobetasone, clobetasol propionate, fluticasone, hydrocortisone butyrate and mometasone are already a part of the schedule.

We would also like the addition of a sentence to the footnote, which states “All corticosteroid molecules for topical or systemic administration introduced in future would be a part of schedule H by default”. Attached is the suggested footnote with the modifications.
The agenda for the meeting regarding this issue could be “CONSIDERATION OF THE PROPOSAL FOR AMENDMENT OF SCHEDULE H OF DRUGS AND COSMETICS RULES, 1945 TO FIGHT TOPICAL STEROID ABUSE”.

We are grateful for your active interest in our cause and thank you for including this issue in the agenda of the forthcoming DTAB meeting. We look forward to your cooperation in fighting the menace of topical steroid abuse in India. Without the support of the legislation and law enforcers like you, our crusade would be unrewarding.

Yours sincerely

Dr. Devesh Mishra
President, IADVL

Dr. Shyamanta Barua
Hon. Secretary General, IADVL

Attachments
1. Suggested footnote of schedule H
2. List of steroids to be included in schedule H